Clinical Trials Logo

Clinical Trial Summary

The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the long-term safety of tirabrutinib as a monotherapy and in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies. This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and in combination with other anti-cancer therapies. As of Amendment 9, all participants currently on the study who have no clinical evidence of disease progression will transition into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to receive treatment via named patient use (or individual expanded use) will be enrolled into the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any participant is an additional 6 years from the date of this amendment (ie. until November 2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to participants who are currently receiving entospletinib. Participants treated with entospletinib as part of a combination regimen with tirabrutinib will stop receiving entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg tablets until study completion. Participants assigned to the 50 mg tablet will be given the option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02457598
Study type Interventional
Source Gilead Sciences
Contact
Status Active, not recruiting
Phase Phase 1
Start date June 16, 2015
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT02343120 - Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Phase 1/Phase 2
Completed NCT02018861 - A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Phase 1/Phase 2
Terminated NCT03701438 - Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Completed NCT04551963 - Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Phase 1
Recruiting NCT05683717 - A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Completed NCT01775631 - Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Phase 1
Active, not recruiting NCT01905813 - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Phase 1
Recruiting NCT05275504 - Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Recruiting NCT03050190 - A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT03125577 - Combination CAR-T Cell Therapy Targeting Hematological Malignancies Phase 1/Phase 2
Recruiting NCT04170283 - Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies Phase 3
Recruiting NCT04509700 - Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Phase 2
Not yet recruiting NCT03642496 - Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies Early Phase 1
Completed NCT00983619 - A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies Phase 1/Phase 2